Siraj M. Ali

Vamsidhar Velcheti, Philip J. Stephens, Vincent A. Miller, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.

Philip J. Stephens, James X. Sun, Garrett M. Frampton, 2016 .

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

Doron Lipson, Bernard Fendler, Jeffrey P. Gregg, 2018, The Journal of molecular diagnostics : JMD.

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.

L. Mariani, J. Ross, F. Montorsi, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.

D. Hsiang, V. Miller, Siraj M. Ali, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib

J. Ross, V. Velcheti, Siraj M. Ali, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers

Howard Kaufman, Shridar Ganesan, Joseph R. Bertino, 2016, The oncologist.

FGFR3–TACC3: A novel gene fusion in cervical cancer

Emily Berry, Alvaro Restrepo, Melissa L. Johnson, 2015, Gynecologic oncology reports.

Clinicopathologic Features of a Series of Primary Renal CIC-rearranged Sarcomas With Comprehensive Molecular Analysis

M. Shago, J. Ross, P. Argani, 2018, The American journal of surgical pathology.

Clinical and immunological implications of frameshift mutations in lung cancer.

Jeffrey H. Chuang, J. Ross, E. Sokol, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Novel SDHA-deficient Renal Cell Carcinoma Revealed by Comprehensive Genomic Profiling

J. Ross, Siraj M. Ali, A. Brodsky, 2015, The American journal of surgical pathology.

Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.

J. Ross, U. Capitanio, F. Montorsi, 2019, European urology.

Biliary cancer: Utility of next‐generation sequencing for clinical management

P. Stephens, H. Kang, V. Miller, 2016, Cancer.

Structure of S6 Kinase 1 Determines whether Raptor-mTOR or Rictor-mTOR Phosphorylates Its Hydrophobic Motif Site*♦

D. Sabatini, Siraj M. Ali, 2005, Journal of Biological Chemistry.

Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study.

J. Ross, F. Montorsi, A. Salonia, 2020, Clinical genitourinary cancer.

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.

J. Ross, A. Maitra, V. Miller, 2019, Gastroenterology.

Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.

J. Ross, V. Miller, G. Frampton, 2019, Journal of the American Academy of Dermatology.

Evaluation of microsatellite instability (MSI) status in gastrointestinal (GI) tumor samples tested with comprehensive genomic profiling (CGP).

James X. Sun, R. Yelensky, V. Miller, 2016 .

CLINICAL AND GENOMIC CHARACTERISTICS OF SMALL CELL LUNG CANCER IN NEVER-SMOKERS: RESULTS FROM A RETROSPECTIVE MULTICENTER COHORT STUDY.

Jun S. Wei, I. Wistuba, V. Rajapakse, 2020, Chest.

A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma

Kai Wang, Timothy A Jennings, Doron Lipson, 2013, Clinical Cancer Research.

Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets

David M. Jones, P. Stephens, R. Yelensky, 2015, Journal of Clinical Pathology.

ComprehensiveGenomicProfilingofAdvancedEsophagealSquamous CellCarcinomasandEsophagealAdenocarcinomasRevealsSimilarities and Differences

P. Stephens, R. Yelensky, J. Ross, 2015 .

Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.

James X. Sun, J. Ross, V. Miller, 2016 .

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer

Franziska Haderk, Siraj M. Ali, D. Tan, 2020, bioRxiv.

Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib.

P. Stephens, J. Ross, D. Lipson, 2014, Clinical breast cancer.

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

P. Stephens, J. Ross, M. Rosenzweig, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping

S. Ou, V. Miller, Siraj M. Ali, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation

Benjamin P. Brown, J. Ross, J. Meiler, 2019, Clinical Cancer Research.

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

P. Stephens, J. Ross, S. Ou, 2015, Lung cancer.

BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy

P. Stephens, J. Ross, J. Sosman, 2018, Pigment cell & melanoma research.

Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy.

P. Stephens, S. Ou, Siraj M. Ali, 2016, JAMA oncology.

Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens.

J. Ross, S. Ganesan, V. Miller, 2018, Blood.

Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.

S. Ou, Siraj M. Ali, A. Schrock, 2017, Lung cancer.

Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.

G. Bhanot, E. White, S. Ganesan, 2018, Journal of the National Cancer Institute.

NewRoutes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing

R. Yelensky, D. Lipson, É., 2014 .

Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.

J. Sosman, V. Miller, G. Daniels, 2017, The oncologist.

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling

P. Stephens, S. Ou, B. Halmos, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.

S. Ou, V. Miller, Siraj M. Ali, 2015, Lung cancer.

ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.

S. Ou, V. Miller, Siraj M. Ali, 2016, Lung cancer.

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.

S. Ou, V. Miller, Siraj M. Ali, 2016, Lung cancer.

Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing

P. Stephens, R. Yelensky, S. Ou, 2016, Clinical Cancer Research.

Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study

P. Stephens, V. Miller, D. Khaira, 2016, Breast Cancer Research and Treatment.

Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.

P. Stephens, D. Lipson, S. Ou, 2018, The oncologist.

Identification of NTRK fusions in pediatric mesenchymal tumors

P. Stephens, K. Badizadegan, M. Rosenzweig, 2017, Pediatric blood & cancer.

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies

K. Hess, J. Heymach, F. Meric-Bernstam, 2020, ESMO Open.

RET rearrangements are actionable alterations in breast cancer

Bhavna S. Paratala, Bahar Yilmazel, B. Leyland-Jones, 2018, Nature Communications.

ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.

David M. Jones, P. Stephens, G. Frampton, 2017, The oncologist.

TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations

Siraj M. Ali, R. Madison, A. Taber, 2019, Lung Cancer.

STUMP un“stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion

P. Stephens, V. Miller, Siraj M. Ali, 2015, Journal of Hematology & Oncology.

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies

B. Tuch, O. Abdel-Wahab, M. Arcila, 2018, The Journal of clinical investigation.

Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal Cancer

E. Sokol, S. Ganesan, S. De, 2022, JCO precision oncology.

Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.

R. Warnke, J. Zehnder, Siraj M. Ali, 2018, Blood advances.

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary

D. Lipson, V. Miller, Siraj M. Ali, 2014, Case Reports in Oncology.

FRMD4A/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.

V. Velcheti, Siraj M. Ali, S. Mukhopadhyay, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature

S. Ou, Siraj M. Ali, A. Schrock, 2017, Lung Cancer.

Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer.

R. Yelensky, D. Lipson, V. Miller, 2013 .

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.

O. Elemento, C. Mason, J. Leonard, 2014, Cancer discovery.

Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy.

V. Miller, S. Millis, J. Suh, 2020, European urology focus.

Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.

V. Miller, A. Futreal, Siraj M. Ali, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Calcineurin Associated with the lnositol 1,4,5=Trisphosphate Receptor-FKBPI 2 Complex Modulates Ca*+ Flux

S. Snyder, G. Ronnett, Siraj M. Ali, 1995 .

SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association

R. Erlich, D. Lin, Siraj M. Ali, 2019, Modern Pathology.

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Xiaoping Zhou, V. Miller, Siraj M. Ali, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Chang S. Chan, E. Cuppen, L. Wessels, 2022, Nature.

signaling S 6 K pathway − TORC 1 Drosophila melanogaster regulators of Genome-scale RNAi on living-cell microarrays identifies novel Material Supplemental

Anne E Carpenter, Katherine L. Madden, T. Jones, 2011 .

Significant Clinical Response to a MEK Inhibitor Therapy in a Patient With Metastatic Melanoma Harboring an RAF1 Fusion.

M. Singer, Siraj M. Ali, Kevin B. Kim, 2018, JCO precision oncology.

Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.

P. Ladenson, V. Miller, G. Frampton, 2018, The oncologist.

Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.

S. Ganesan, Siraj M. Ali, K. Hirshfield, 2015, European urology.

Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer.

U. Capitanio, F. Montorsi, A. Salonia, 2020, Journal of the National Cancer Institute.

Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

Narasimhan P. Agaram, Narasimhan P Agaram, M. Ladanyi, 2022, Nature Communications.

Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics

S. Millis, R. Kurzrock, Siraj M. Ali, 2021, The oncologist.

Abstract P2-09-15: NTRK fusions in breast cancer: Clinical, pathologic and genomic findings

V. Miller, G. Frampton, J. Suh, 2018 .

Exceptional Response to Palbociclib in Metastatic Collecting Duct Carcinoma Bearing a CDKN2A Homozygous Deletion.

T. Choueiri, Siraj M. Ali, S. Pal, 2017, JCO precision oncology.

Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.

Siraj M. Ali, S. Pal, N. Palma, 2015, European urology.

RAS-amplified colorectal cancers: Microsatellite stability status, RAS/BRAF mutations, and prediction of anti-EGFR resistance.

V. Miller, M. Fakih, Siraj M. Ali, 2019, Journal of Clinical Oncology.

Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).

V. Miller, G. Frampton, M. Borad, 2019, Journal of Clinical Oncology.

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

S. Ou, Siraj M. Ali, J. Milliken, 2017, Lung cancer.

Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors.

V. Miller, Siraj M. Ali, E. Severson, 2019, European urology focus.

Identification of a novel fusion TBL1XR1–PDGFRB in a patient with acute myeloid leukemia harboring the DEK–NUP214 fusion and clinical response to dasatinib

V. Miller, P. Campregher, Siraj M. Ali, 2017, Leukemia & lymphoma.

General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.

P. Stephens, V. Miller, G. Frampton, 2017, Human pathology.

Comprehensive genomic profiling of malignant phyllodes tumors of the breast

P. Stephens, S. Ganesan, V. Miller, 2017, Breast Cancer Research and Treatment.

Comprehensive genomic profiling of ctDNA in patients with colon cancer and its fidelity to the genomics of the tumor biopsy.

T. Clark, J. Gregg, D. Lipson, 2018 .

Intracranial Activity of Cabozantinib in MET Exon 14–Positive NSCLC with Brain Metastases

S. Ou, Siraj M. Ali, A. Borghei, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Mark Rosenzweig, Joel Greshock, Doron Lipson, 2015, Cancer discovery.

Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux

S. Snyder, Siraj M. Ali, A. Roskams, 1995, Cell.

De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.

D. Costa, Siraj M. Ali, K. Gowen, 2017, Lung cancer.

Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.

P. Stephens, S. Ou, V. Miller, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib.

Siraj M. Ali, A. Schrock, A. Chachoua, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature

Siraj M. Ali, J. Hoffman-Censits, E. Trabulsi, 2017, Clinical genitourinary cancer.

Treatment of Patients With Lobular Breast Cancer Harboring Human Epidermal Growth Factor Receptor 2 Mutation With HER2-Directed Therapy.

Siraj M. Ali, D. Citrin, Nimesh B Patel, 2018, JCO precision oncology.

Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors

S. Millis, R. Kurzrock, Siraj M. Ali, 2022, The oncologist.

Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes.

P. Stephens, R. Yelensky, W. Pao, 2014, Cancer discovery.

WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.

V. Velcheti, Siraj M. Ali, R. Madison, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib.

P. Stephens, R. Yelensky, V. Miller, 2016, Journal of the National Cancer Institute.

The Genomics of Colorectal Cancer in Populations with African and European Ancestry

K. Pradhan, Amit Verma, G. Frampton, 2022, Cancer discovery.

BRAF fusions in clinically advanced non-small cell lung cancer: An emerging target for anti-BRAF therapies.

V. Miller, G. Frampton, J. Suh, 2017 .

Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex

D. Guertin, D. Sabatini, Siraj M. Ali, 2005, Science.

Comprehensive Genomic Profiling of Relapsed and Metastatic Adenoid Cystic Carcinomas by Next-generation Sequencing Reveals Potential New Routes to Targeted Therapies

P. Stephens, R. Yelensky, D. Lipson, 2014, The American journal of surgical pathology.

Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations

P. Stephens, R. Yelensky, D. Lipson, 2016, Clinical Cancer Research.

Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry

A. Drilon, M. Okada, S. Ou, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.

S. Millis, Siraj M. Ali, H. Kaplan, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large‐Scale Data to Inform Therapeutic Directions

S. Millis, R. Kurzrock, Siraj M. Ali, 2020, The oncologist.

Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations

James X. Sun, P. Stephens, R. Yelensky, 2013, Clinical Cancer Research.

Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity

J. Gregg, N. Agarwal, E. Sokol, 2020, JCO precision oncology.

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus

J. Sicklick, P. Stephens, B. Leyland-Jones, 2018, Clinical Cancer Research.

Biallelic Deletion of PALB2 Occurs Across Multiple Tumor Types and Suggests Responsiveness to Poly (ADP-ribose) Polymerase Inhibition.

Siraj M. Ali, A. Schrock, S. Klempner, 2017, JCO precision oncology.

Genomic Profiling of Small-Bowel Adenocarcinoma

James X. Sun, P. Stephens, V. Miller, 2017, JAMA oncology.

The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

Kai Wang, Doron Lipson, Roman Yelensky, 2015, International journal of cancer.

Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations

P. Stephens, V. Miller, D. Khaira, 2015, Breast Cancer Research and Treatment.

A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy

P. Stephens, R. Yelensky, B. Leyland-Jones, 2015, OncoTargets and therapy.

Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.

P. Stephens, V. Miller, Siraj M. Ali, 2017, JCI insight.

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

B. Taylor, P. Stephens, J. Baselga, 2016, Cancer discovery.

Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra.

Trevor J Pugh, James X. Sun, P. Stephens, 2017, Cancer research.

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies

P. Stephens, R. Yelensky, R. Bose, 2016, Cancer.

Abstract P3-07-05: Non-amplification ERBB2 genomic alterations in 5,605 cases of refractory and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies

R. Yelensky, D. Lipson, V. Miller, 2016 .

Targetable gene fusions and aberrations in genitourinary oncology

Siraj M. Ali, L. Marandino, R. Madison, 2020, Nature Reviews Urology.

Squamous Transformation of Prostate Adenocarcinoma: A Report of Two Cases With Genomic Profiling.

Siraj M. Ali, S. Pal, Huiqing Wu, 2019, Clinical genitourinary cancer.

Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation.

E. Perez, Siraj M. Ali, S. Balasubramanian, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Diverse EGFR Exon 20 Insertions and Co‐Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

J. McPherson, P. Stephens, J. Riess, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors

J. Gregg, E. Sokol, J. Riess, 2021, Translational oncology.

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.

E. Sokol, G. Frampton, D. Fabrizio, 2019, The oncologist.

Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy

P. Stephens, V. Miller, Siraj M. Ali, 2019, The Journal of urology.

Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling

V. Miller, Siraj M. Ali, S. Gadgeel, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

James X. Sun, V. Miller, G. Frampton, 2018, Journal of gastrointestinal oncology.

Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma.

Siraj M. Ali, J. Elvin, P. Boasberg, 2018, The oncologist.

Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.

P. Stephens, T. Choueiri, N. Agarwal, 2018, European urology.

Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors.

Gyan Bhanot, Shridar Ganesan, G. Bhanot, 2017, JCO precision oncology.

Genomic Profiling to Expand Management Options for Locally Advanced Esophagogastric Cancers: A Proof of Principle Case.

Siraj M. Ali, A. Schrock, J. Chao, 2017, JCO precision oncology.

Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

V. Wang, V. Miller, Siraj M. Ali, 2017, Journal of Immunotherapy for Cancer.

Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy

P. Stephens, G. Chirn, V. Miller, 2017, Cancer.

Inactivation of Capicua drives cancer metastasis

S. Asthana, Matan Hofree, V. Miller, 2016, Nature Genetics.

Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.

W. Bulman, A. Saqi, V. Miller, 2016, Clinical lung cancer.

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.

Gyan Bhanot, Shridar Ganesan, Hua Zhong, 2016, The Journal of clinical investigation.

Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response.

P. Stephens, T. Ho, T. Choueiri, 2016, European urology focus.

First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.

James X. Sun, F. Meric-Bernstam, D. Fabrizio, 2017, JCI insight.

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors

S. Ou, V. Miller, Siraj M. Ali, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.

David M. Jones, P. Stephens, R. Yelensky, 2014, The oncologist.

Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.

P. Stephens, R. Yelensky, D. Lipson, 2015, The oncologist.

Relapsed classic E-cadherin (CDH1) mutated invasive lobular breast cancer demonstrates a high frequency of HER2 (ERBB2) gene mutations

James X. Sun, P. Stephens, R. Yelensky, 2013 .

Human Cancer Biology Relapsed Classic E-Cadherin ( CDH 1 ) – Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER 2 ( ERBB 2 ) Gene Mutations

James X. Sun, P. Stephens, R. Yelensky, 2013 .

Kinase domain activation through gene rearrangement in multiple myeloma

O. Stephens, G. Morgan, V. Miller, 2018, Leukemia.

Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.

P. Stephens, R. Yelensky, D. Lipson, 2015, The oncologist.

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

P. Stephens, R. Yelensky, S. Ou, 2015, The oncologist.

Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors

J. Gregg, N. Agarwal, E. Sokol, 2019, JCO precision oncology.

Phosphatidylinositol 3‐kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities

V. Miller, S. Millis, R. Kurzrock, 2018, Cancer.

Aggressive-Variant Microsatellite-Stable POLE Mutant Prostate Cancer With High Mutation Burden and Durable Response to Immune Checkpoint Inhibitor Therapy.

E. Sokol, Siraj M. Ali, D. Reed, 2018, JCO precision oncology.

Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target

James X. Sun, P. Stephens, V. Miller, 2016, Clinical Cancer Research.

Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas

P. Stephens, V. Miller, F. Meric-Bernstam, 2017, Oncotarget.

Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome

P. Raman, I. Ostrovnaya, J. Maris, 2016, PLoS genetics.

Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting

Benjamin P. Brown, M. Ladanyi, J. Meiler, 2021, Nature Communications.

Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions

V. Miller, B. Alexander, D. Lin, 2020, BJU international.

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer

P. Stephens, A. Shaw, S. Ou, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients

D. Lipson, V. Miller, Siraj M. Ali, 2017, Clinical lung cancer.

Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.

S. Ou, V. Miller, Siraj M. Ali, 2017, The oncologist.

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.

P. Stephens, V. Miller, G. Frampton, 2016, The oncologist.

Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma

P. Stephens, V. Miller, M. Kaag, 2016, Oncotarget.

Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative

S. Paik, Siraj M. Ali, S. Lim, 2016, Oncotarget.

MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor.

G. Frampton, Siraj M. Ali, Carrie Lee, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling.

P. Stephens, S. Ou, V. Miller, 2015, Lung cancer.

Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib

Ximing J. Yang, S. Abdulkadir, Siraj M. Ali, 2018, Clinical Cancer Research.

Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma

C. Chung, V. Miller, Siraj M. Ali, 2017, Head & neck.

Abstract 1118: Activation of MET via diverse exon 14 skipping mutations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors

Alex M. Fichtenholtz, P. Stephens, R. Yelensky, 2015 .

Genome-scale RNAi on living-cell microarrays identifies novel regulators of Drosophila melanogaster TORC1-S6K pathway signaling.

Anne E Carpenter, David M Sabatini, Thouis R Jones, 2011, Genome research.

Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.

E. Sokol, V. Miller, G. Frampton, 2019, The oncologist.

RICTOR Amplifi cation Defi nes a Novel Subset of Patients with Lung Cancer Who May Benefi t from Treatment with mTORC 1 / 2 Inhibitors

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

D. Sabatini, Siraj M. Ali, Shomit Sengupta, 2006, Molecular cell.

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA

E. Sokol, K. Abhishek, S. Ganesan, 2019, The oncologist.

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.

Kai Wang, Roman Yelensky, Gary Palmer, 2015, JAMA oncology.

Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted Therapies

V. Miller, Y. Shyr, A. Greenplate, 2018, JCO precision oncology.

Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.

P. Stephens, R. Yelensky, D. Lipson, 2015, Archives of pathology & laboratory medicine.

Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile.

G. Cancel-Tassin, E. Compérat, Siraj M. Ali, 2020, European urology oncology.

Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.

V. Miller, B. Alexander, Siraj M. Ali, 2020, European urology.

Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.

U. Capitanio, F. Montorsi, A. Salonia, 2019, European urology.

Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.

R. Salgia, Siraj M. Ali, R. Madison, 2018, European urology.

Identification and characterization of RET fusions in advanced colorectal cancer

P. Stephens, V. Miller, Siraj M. Ali, 2015, Oncotarget.

Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling.

P. Stephens, R. Yelensky, E. V. Van Allen, 2016, European urology.

Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA

S. Ganesan, M. Rosenzweig, V. Miller, 2020, Oncology.

Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients

Z. Ram, Siraj M. Ali, D. Blumenthal, 2016, Journal of Neuro-Oncology.

Identification of novel fumarate hydratase gene alterations in prostate cancer.

V. Miller, S. Millis, Siraj M. Ali, 2017 .

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

M. Ladanyi, M. Zauderer, R. Yelensky, 2016, The oncologist.

Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.

Shridar Ganesan, R. DiPaola, S. Ganesan, 2016, Gynecologic oncology.

Successful Treatment of Recurrent Primitive Myxoid Mesenchymal Tumor of Infancy With BCOR Internal Tandem Duplication.

Siraj M. Ali, J. Pressey, Rong Li, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma

P. Stephens, S. Signoretti, A. Hakimi, 2018, British Journal of Cancer.

Comprehensive Genomic Profiling of Renal Cell Carcinoma at Initial Diagnosis and Putative Local Recurrence.

V. Miller, G. Frampton, Siraj M. Ali, 2016, European urology focus.

Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report

Siraj M. Ali, R. Madison, A. Schrock, 2017, BMC Cancer.

Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.

P. Stephens, P. Tamboli, E. Jonasch, 2016, European urology.

Identification of ANLN as ETV6 partner gene in recurrent t(7;12)(p15;p13): a possible role of deregulated ANLN expression in leukemogenesis

V. Miller, P. Campregher, Siraj M. Ali, 2015, Molecular Cancer.

Evaluation of 122 advanced‐stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies

P. Stephens, R. Yelensky, M. Mihm, 2016, Cancer.

Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss.

D. Lin, Siraj M. Ali, E. Severson, 2020, Gynecologic oncology.

Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.

D. Lin, Siraj M. Ali, J. Elvin, 2017, Gynecologic oncology.

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

Kai Wang, Doron Lipson, Roman Yelensky, 2014, Modern Pathology.

Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation

V. Miller, Siraj M. Ali, S. Pal, 2020, Case Reports in Oncology.

A Common Cell of Origin for Inflammatory Myofibroblastic Tumor and Lung Adenocarcinoma with ALK rearrangement.

A. Borowsky, J. Riess, B. Alexander, 2022, Clinical lung cancer.

Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy

D. Cappellen, Siraj M. Ali, C. Robert, 2021, JCO precision oncology.

Real-world association of HER2/ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer.

B. Alexander, Siraj M. Ali, R. Madison, 2021, Future oncology.

Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma

V. Miller, G. Frampton, B. Alexander, 2021, JCO precision oncology.

Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas

V. Miller, A. Sapino, B. Alexander, 2021, Clinical Cancer Research.

Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.

N. Agarwal, G. Sonpavde, V. Miller, 2020, European urology focus.

Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.

J. Gregg, V. Miller, B. Alexander, 2020, Lung cancer.

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors

J. Riess, M. Rosenzweig, V. Miller, 2020, Lung Cancer.

Clinicopathologic Characteristics of BRG1-Deficient Non-Small Cell Lung Cancer.

M. Mino‐Kenudson, A. Shaw, J. Lennerz, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.

Jeffrey W. Clark, V. Miller, G. Frampton, 2019, The oncologist.

Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients

G. Frampton, J. Newberg, E. Golemis, 2019, Nature Communications.

MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation.

J. Gregg, J. Riess, V. Miller, 2019, The oncologist.

FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape

V. Miller, Siraj M. Ali, R. Madison, 2019, The oncologist.

Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling

Yang Xie, D. Gerber, D. Sher, 2019, Head & neck.

TNS1-ALK Fusion in a Recurrent, Metastatic Uterine Mesenchymal Tumor Originally Diagnosed as Leiomyosarcoma.

D. Lin, Siraj M. Ali, S. Klempner, 2019, Acta medica academica.

Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion.

V. Miller, Siraj M. Ali, C. Lovly, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC

G. Giaccone, J. Gregg, P. Stephens, 2018, PloS one.

Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors

T. Clark, J. Gregg, P. Stephens, 2018, Journal of Hematology & Oncology.

A Pan-Cancer Landscape Analysis Reveals a Subset of Endometrial Stromal and Pediatric Tumors Defined by Internal Tandem Duplications of BCOR

D. Lin, Siraj M. Ali, R. Madison, 2018, Oncology.

BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations.

S. Ganesan, M. Rosenzweig, S. Ou, 2018, JCO precision oncology.

Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure.

Siraj M. Ali, D. Raggi, A. Alessi, 2018, European journal of cancer.

Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer

S. Ganesan, J. Amorosa, Siraj M. Ali, 2018, Cold Spring Harbor molecular case studies.

ATM/RB1 mutations predict shorter overall survival in urothelial cancer

Siraj M. Ali, P. Mendiratta, P. Grivas, 2018, Oncotarget.

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

A. Iafrate, P. Stephens, A. Shaw, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data.

S. Ganesan, Hossein Khiabanian, Siraj M. Ali, 2018, JCO precision oncology.

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3

James X. Sun, P. Stephens, V. Miller, 2018, Cancer.

OP-JNCI170289 316..320

G. Bhanot, E. White, S. Ganesan, 2018 .

Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients

S. Ou, V. Miller, Siraj M. Ali, 2017, Lung cancer.

Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options.

P. Stephens, V. Miller, J. Suh, 2017, The oncologist.

Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.

V. Miller, Siraj M. Ali, L. Raez, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.

M. Ahn, E. Cho, Siraj M. Ali, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture‐Based Assay of Circulating Tumor DNA

V. Miller, R. Erlich, Siraj M. Ali, 2017, The oncologist.

Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.

Jesse S. Voss, James X. Sun, A. Grothey, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.

V. Miller, V. Velcheti, Siraj M. Ali, 2017, Clinical lung cancer.

Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.

P. Stephens, S. Ou, V. Miller, 2017, Clinical lung cancer.

Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.

J. Lacy, M. Nikiforova, Siraj M. Ali, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.

P. Stephens, V. Miller, G. Frampton, 2017, The oncologist.

A recurrent endometrial stromal sarcoma harbors the novel fusion JAZF1-BCORL1

Siraj M. Ali, K. Gowen, J. Elvin, 2017, Gynecologic oncology reports.

Molecular Profiling of Synchronous Colon Cancers and Anaplastic Thyroid Cancer in a Patient with Lynch Syndrome

Siraj M. Ali, D. Cognetti, M. Tuluc, 2018, Journal of Gastrointestinal Cancer.

FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors

J. Sicklick, O. Harismendy, James D. Murphy, 2016, Journal of Translational Medicine.

Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma.

P. Stephens, V. Miller, Siraj M. Ali, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion

P. Stephens, V. Miller, F. Meric-Bernstam, 2016, Oncology.

Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.

James X. Sun, P. Stephens, V. Miller, 2016, The oncologist.

High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.

S. Ou, Siraj M. Ali, N. Agarwal, 2016, Lung cancer.

TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.

S. Ou, Siraj M. Ali, K. Gowen, 2016, Lung cancer.

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.

P. Stephens, M. Erlander, S. Ou, 2016, Cancer discovery.

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Jens Meiler, Taofeek K Owonikoko, Jonathan H Sheehan, 2016, Cancer discovery.

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma

James X. Sun, P. Stephens, R. Yelensky, 2016, Oncology.

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations

P. Stephens, R. Yelensky, D. Lipson, 2016, Cancer.

Novel FNDC3B and MECOM fusion and WT1 L378fs* 7 frameshift mutation in an acute myeloid leukaemia patient with cytomorphological and immunophenotypic features reminiscent of acute promyelocytic leukaemia

Siraj M. Ali, L. Young, Huan-You Wang, 2016, British journal of haematology.

A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient

Siraj M. Ali, Kai Wang, Jon H. Chung, 2016, Case Reports in Oncology.

Missed clinical benefit due to false negatives in testing for EGFR T790M mutations in non-small cell lung cancer

P. Stephens, S. Ou, V. Miller, 2016 .

Genomic profiling and treatment of HER2+, ER+, PgR+ “triple positive” breast cancer: A case report and literature review

M. Koehler, Siraj M. Ali, R. Schwab, 2016 .

Renal carcinoma associated with a novel succinate dehydrogenase A mutation: a case report and review of literature of a rare subtype of renal carcinoma.

G. Netto, Siraj M. Ali, O. Sanli, 2015, Human pathology.

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.

M. Ladanyi, M. Kris, J. Meiler, 2015, Cancer discovery.

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

Sanjay Goel, Kai Wang, Amit Verma, 2015, Cancer discovery.

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.

S. Kobayashi, V. Miller, D. Costa, 2015, Clinical lung cancer.

Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.

P. Stephens, V. Miller, Siraj M. Ali, 2015, European urology.

Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification

P. Stephens, R. Yelensky, Bahar Yilmazel, 2015, Oncoscience.

Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening

Joon-Oh Park, P. Stephens, J. Huh, 2015, Oncotarget.

Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation.

V. Miller, Siraj M. Ali, S. Pal, 2015, European urology.

Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus.

H. MacMahon, V. Miller, R. Salgia, 2014, Case reports in clinical pathology.

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib

D. Lipson, V. Miller, Siraj M. Ali, 2014, Case Reports in Oncology.

Successful treatment of a patient with Li–Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib

B. Halmos, V. Miller, Siraj M. Ali, 2014, Cancer biology & therapy.

Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein

V. Miller, Siraj M. Ali, S. Westin, 2014, Journal of Hematology & Oncology.

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma

S. Millis, A. Goodman, R. Kurzrock, 2019, Oncotarget.

An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis.

L. Mariani, Siraj M. Ali, D. Raggi, 2019, European urology.

Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Non-Small-Cell Lung Cancer.

F. Meric-Bernstam, Siraj M. Ali, D. Hong, 2019, JCO precision oncology.

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.

P. Stephens, S. Ou, V. Miller, 2017, Lung cancer.

A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases

V. Wang, V. Miller, Siraj M. Ali, 2017, The oncologist.

Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors

V. Miller, G. Frampton, Siraj M. Ali, 2018, Oncotarget.

BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma

E. White, S. Ganesan, Siraj M. Ali, 2017, Clinical Cancer Research.

Prospective Decision Analysis Study of Clinical Genomic Testing in Metastatic Breast Cancer: Impact on Outcomes and Patient Perceptions.

B. Ramaswamy, C. Shapiro, Siraj M. Ali, 2019, JCO precision oncology.

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation

S. Ou, Siraj M. Ali, A. Schrock, 2018, Lung Cancer.

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer

Lauren L. Ritterhouse, A. Iafrate, M. Mino‐Kenudson, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genomic Landscape of Appendiceal Neoplasms.

Justin K. Huang, T. Ideker, O. Harismendy, 2018, JCO precision oncology.

BRAF fusion as a novel mechanism of acquired resistance to vemurafenib in BRAF V 600 E mutant 3 melanoma 4 5

E. White, S. Ganesan, Siraj M. Ali, 2017 .

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus

In Seok Yang, Min Goo Lee, Hyo Song Kim, 2016, Oncotarget.

Abstract A23: Comprehensive next-generation sequencing-based genomic profiling identifies actionable genomic alterations in diverse pediatric tumor types: The Foundation Medicine (FMI) experience

P. Stephens, R. Yelensky, V. Miller, 2014 .

A case of advanced infantile myofibromatosis harboring a novel MYH10‐RET fusion

P. Stephens, M. Rosenzweig, V. Miller, 2017, Pediatric blood & cancer.

Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib

P. Leavey, D. Rakheja, M. Rosenzweig, 2019, Cold Spring Harbor molecular case studies.

Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.

V. Miller, Siraj M. Ali, V. Subbiah, 2015, Lung cancer.

Large-Cell Neuroendocrine Carcinoma of the Lung: A Focused Analysis of BRAF Alterations and Case Report of a BRAF Non-V600-Mutated Tumor Responding to Targeted Therapy.

V. Miller, Siraj M. Ali, F. Giles, 2018, JCO precision oncology.

Recurrent secondary genomic alterations in desmoplastic small round cell tumors

S. Millis, Siraj M. Ali, Xiwei Wu, 2020, BMC Medical Genetics.

Targeted treatment of RAI-resistant metastatic thyroid cancer postcomprehensive genomic profiling.

P. Stephens, S. Ganesan, V. Miller, 2014 .

Sclerosing epithelioid fibrosarcoma presenting as intraabdominal sarcomatosis with a novel EWSR1-CREB3L1 gene fusion.

Siraj M. Ali, Jié He, J. Meis, 2014, Human pathology.

Primary Spinal Epidural CIC-DUX4 Undifferentiated Sarcoma in a Child

Siraj M. Ali, S. M. de la Monte, D. Treaba, 2018, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

Primary Undifferentiated Sarcoma of the Kidney Harboring a Novel Variant of CIC-DUX4 Gene Fusion.

M. Shago, Siraj M. Ali, D. Treaba, 2016, The American journal of surgical pathology.

Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.

V. Miller, S. Millis, R. Maki, 2017 .

A prolonged response to platinum‐based therapy in a patient with metastatic urothelial carcinoma harboring a single rearranged and truncated NF2 gene

R. Dhir, Siraj M. Ali, S. Gollin, 2018, Genes, chromosomes & cancer.

FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors

J. Sicklick, O. Harismendy, James D. Murphy, 2016, Journal of Translational Medicine.

Durable Clinical Response to Larotrectinib in an Adolescent Patient With an Undifferentiated Sarcoma Harboring an STRN-NTRK2 Fusion

V. Miller, S. Megison, Siraj M. Ali, 2018, JCO precision oncology.

The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review.

S. Ou, V. Miller, D. Costa, 2015, Clinical lung cancer.

849PDComparison of tumor mutational burden (TMB) in relevant molecular subsets of metastatic urothelial cancer (MUC)

T. Choueiri, N. Agarwal, V. Miller, 2017 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Comprehensive genomic profiling of gallbladder adenocarcinoma and frequent genomic-derived targets of therapy.

G. Frampton, Siraj M. Ali, N. Palma, 2014 .

Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma.

R. Yelensky, S. Ou, D. Lipson, 2014 .

Rapid Response to Larotrectinib (LOXO‐101) in an Adult Chemotherapy‐Naive Patients With Advanced Triple‐Negative Secretory Breast Cancer Expressing ETV6‐NTRK3 Fusion

Siraj M. Ali, R. Yerushalmi, N. Peled, 2017, Clinical breast cancer.

NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry.

A. Drilon, J. Shih, R. Doebele, 2019, Journal of Clinical Oncology.

Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.

P. Stephens, R. Yelensky, D. Lipson, 2016, The oncologist.

Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies.

Siraj M. Ali, G. Bratslavsky, R. Madison, 2019, European urology oncology.

Unique genomic features in adolescent and young adult, as compared to older adult, non‐Hodgkin lymphoma and potential therapeutic targets

P. Stephens, R. Yelensky, D. Lipson, 2017, British journal of haematology.

Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Molecular Characterization of Gallbladder Cancer using Somatic Mutation Profiling

S. Curley, A. Rashid, Siraj M. Ali, 2013, Human pathology.

Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.

R. Sullivan, Dennie T. Frederick, J. Sosman, 2016 .

Genomic Features for Therapeutic Insights of Chemotherapy-Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors and Comparison with Gonadal Counterpart.

S. Millis, Siraj M. Ali, G. Bratslavsky, 2019, The oncologist.

Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.

J. Gregg, J. Hughes, V. Miller, 2019, Journal of gastrointestinal oncology.

PBRM1 mutation and immunotherapy efficacy: A comprehensive genomic profiling (CGP) assessment.

E. Sokol, V. Miller, G. Frampton, 2018 .

Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.

F. Hirsch, D. Lipson, P. Bunn, 2015, The oncologist.

Lung Cancer Fluorescence In Situ Hybridization , Immunohistochemistry , and Next-Generation Sequencing for Detection of EML 4-ALK Rearrangement in Lung Cancer

F. Hirsch, D. Lipson, P. Bunn, 2015 .

Atypical RAS Mutations in Metastatic Colorectal Cancer.

V. Miller, R. Yaeger, J. Hechtman, 2019, JCO precision oncology.

Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP).

James X. Sun, R. Yelensky, V. Miller, 2016 .

Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2-Targeted Therapy.

P. Stephens, Runjun D. Kumar, R. Bose, 2017, JCO precision oncology.

Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy.

P. Stephens, D. Lipson, V. Miller, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies.

J. McPherson, P. Stephens, V. Miller, 2017, JCO Precision Oncology.

1140PDPredictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI) – analysis of somatic alterations (SAs)

Siraj M. Ali, D. Kilari, P. Ritch, 2017 .

1OComprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types

S. Ikeda, S. Ganesan, S. Ou, 2017 .

Malignant pheochromocytoma: A comprehensive genomic profiling study.

V. Miller, B. Alexander, Siraj M. Ali, 2019, Journal of Clinical Oncology.

Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden

V. Miller, Siraj M. Ali, M. Markman, 2018, Lung Cancer.

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification

S. Ou, Siraj M. Ali, A. Schrock, 2019, Lung Cancer.

Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.

P. Stephens, S. Ou, V. Miller, 2016, The oncologist.

1138PDImmune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC)

A. Abernethy, V. Miller, G. Frampton, 2017 .

Efficacy of olaparib monotherapy in patients (pts) with HER2-negative metastatic breast cancer (MBC) with germline BRCA mutation (gBRCAm) or lesional BRCA mutation (lBRCAm).

Siraj M. Ali, D. Citrin, M. Markman, 2018 .

Preoperative pembrolizumab (pembro) before radical cystectomy (RC) for muscle-invasive urothelial bladder carcinoma (MIUC): Interim clinical and biomarker findings from the phase 2 PURE-01 study.

F. Montorsi, A. Salonia, N. Fossati, 2018 .

Apache: An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage.

L. Mariani, Siraj M. Ali, D. Raggi, 2018 .

1170PAnalysis of POLE mutation and tumor mutational burden (TMB) across 80,853 tumors: Implications for immune checkpoint inhibitors (ICPIs)

V. Miller, D. Fabrizio, M. Fakih, 2017 .

265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

W. Gradishar, Siraj M. Ali, J. O’Shaughnessy, 2021, Annals of Oncology.

Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

1169PTopography of Tumor Mutational Burden (TMB) and Immune-related Genomic Alterations (GA) Across Gastrointestinal Malignancies (GIm): A Study of 22,570 Cases

V. Miller, G. Frampton, Siraj M. Ali, 2017 .

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma.

S. Digumarthy, M. Mino‐Kenudson, A. Shaw, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effect of rice bran oil on the lipid profile of steroid responsive nephrotic syndrome

Siraj M. Ali, K. Afzal, S. Aggarwal, 2005 .

Comprehensive genomic profiling of 443 cases of renal cell carcinoma to reveal frequent clinically relevant genomic alterations.

R. Yelensky, T. Choueiri, D. Lipson, 2015 .

Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets.

F. Montorsi, A. Salonia, N. Agarwal, 2019, Journal of Clinical Oncology.

Unfavourable cancer specific survival after neoadjuvant chemotherapy and radical cystectomy in bladder cancer patients with squamous-cell variant: A multi-institutional study

F. Montorsi, A. Salonia, N. Agarwal, 2021 .

OA 12.08 Genomic Analysis of Non-Small Cell Lung Cancer (NSCLC) Cases with Focal and Non-Focal MET Amplification

S. Ou, V. Miller, Siraj M. Ali, 2017 .

First-inhuman trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients

James X. Sun, F. Meric-Bernstam, D. Fabrizio, 2018 .

MA 12.03 Kinase Fusions as Recurrent Mechanisms of Acquired Resistance in EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

S. Ou, V. Miller, Siraj M. Ali, 2017 .

EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?

Siraj M. Ali, L. Raez, J. Pinto, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CD74-ROS1 Fusion in NSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assays.

V. Wang, V. Miller, Siraj M. Ali, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MA14.01 Updated Dataset Assessing Tumor Mutation Burden (TMB) as a Biomarker for Response to PD-1/PD-L1 Targeted Therapies in Lung Cancer (LC)

James X. Sun, P. Stephens, S. Ou, 2017 .

Relationship of anaplastic thyroid cancer high tumor mutation burden and MSI-H status with response to anti-PD1 monotherapy.

Siraj M. Ali, D. Bowles, M. Beg, 2018 .

Genomic alterations (GA) and tumor mutational burden (TMB) in large cell neuroendocrine carcinoma of lung (L-LCNEC) as compared to small cell lung carcinoma (SCLC) as assessed via comprehensive genomic profiling (CGP).

V. Wang, S. Ganesan, S. Ou, 2017 .

NTRK1-3 genomic fusions in non-small cell lung cancer (NSCLC) determined by comprehensive genomic profiling

E. Sokol, S. Ou, G. Frampton, 2019, Annals of Oncology.

Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy.

V. Miller, B. Esmaeli, Siraj M. Ali, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

James X. Sun, L. Garraway, V. Miller, 2017, Genome Medicine.

Abstract P2-12-01: Comprehensive genomic profiling of 34 cases of breast angiosarcoma

S. Schnitt, V. Miller, S. Millis, 2017 .

Comprehensive genomic profiling of parathyroid carcinoma.

P. Stephens, P. Ladenson, V. Miller, 2017 .

RET rearrangements are actionable alterations in breast cancer

Bhavna S. Paratala, Bahar Yilmazel, B. Leyland-Jones, 2018, Nature Communications.

Genomic profiling of nephrectomy and metastatic sites in patients with advanced clear cell renal cell carcinoma (RCC).

P. Stephens, S. Signoretti, T. Choueiri, 2017 .

Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutation.

S. Ou, V. Miller, Siraj M. Ali, 2018, Lung cancer.

Genomic subtypes of angiosarcoma: A comprehensive genomic profiling (CGP) study.

E. Sokol, V. Miller, G. Frampton, 2018 .

Whole-exome and targeted sequencing of angiosarcomas: Target identification and treatment implications.

A. Protopopov, P. Stephens, V. Miller, 2014 .

Comprehensive genomic profiling of anaplastic thyroid carcinoma.

Siraj M. Ali, D. Bowles, V. Agrawal, 2018 .

Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling

B. Barlogie, G. Morgan, D. Johann, 2014 .

Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion.

K. Hess, D. Carbone, R. Salgia, 2016 .

867PCorrelation of circulating tumor DNA (ctDNA) assessment with tissue-based comprehensive genomic profiling (CGP) in metastatic urothelial cancer (mUC)

Siraj M. Ali, B. McGregor, P. Grivas, 2017 .

Comprehensive genomic profiling of solid tumors from 677 adolescents and young adults for revealing a distinct spectrum of targetable genomic alterations.

R. Yelensky, D. Lipson, V. Miller, 2014 .

Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes.

S. Ganesan, V. Miller, G. Frampton, 2017 .

Acquired ALK L1152R Mutation Confers Resistance to Ceritinib and Predicts Response to Alectinib.

V. Miller, Siraj M. Ali, E. Haura, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MA16.05 MET Kinase Domain Rearrangements (KDRE) in Non-Small Cell Lung Cancer (NSCLC) Identified Through Comprehensive Genomic Profiling (CGP)

M. Rosenzweig, S. Ou, V. Miller, 2018, Journal of Thoracic Oncology.

Loss of Heterozygosity of FLT3-ITD Is Common in Acute Myeloid Leukemia and May be a More Consistent Prognostic Marker Than FLT3-ITD Allele Frequency

E. Sokol, B. Alexander, Siraj M. Ali, 2019, Blood.

Immunotherapy predictive biomarkers in metastatic breast cancer (MBC).

E. Sokol, V. Miller, G. Frampton, 2019, Journal of Clinical Oncology.

Pan-cancer genomic landscape of the cyclin D1/FGF3,4,19 (11q13) amplicon including associations with HPV status, and ESR1 and AR alterations

V. Miller, B. Alexander, Siraj M. Ali, 2019, Annals of Oncology.

PD-L1 expression, tumor mutational burden, and microsatellite instability status in 746 pancreas ductal adenocarcinomas.

V. Miller, G. Frampton, B. Alexander, 2020 .

BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.

P. Stephens, V. Miller, R. Erlich, 2017, Clinical breast cancer.

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Chang S. Chan, L. Wessels, S. Ganesan, 2022, Nature.

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers

James X. Sun, Chang S. Chan, A. Vazquez, 2016, The oncologist.

Comprehensive genomic profiling (CGP) of advanced papillary renal cell carcinoma (PRCC) to reveal distinctions from TCGA dataset.

T. Choueiri, V. Miller, Siraj M. Ali, 2017 .

Acquired CTNNB1 Mutation Drives Immune Checkpoint Inhibitor-Acquired Resistance in a Microsatellite Instability-High Gastroesophageal Adenocarcinoma With Brain Metastases.

Siraj M. Ali, A. Schrock, C. Kubicky, 2019, JCO precision oncology.

Comprehensive genomic profiling identifies a novel TNKS2–PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy

R. Yelensky, V. Miller, G. Frampton, 2015, Blood Cancer Journal.

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer

Adrian V. Lee, B. Leyland-Jones, M. Rosenzweig, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

319 Genomic profiling of uterine leiomyosarcomas reveal frequent alterations in Akt/mammalian target of rapamycin (mTOR) pathway genes and other actionable genomic abnormalities linked to targeted therapies

V. Miller, Siraj M. Ali, J. Elvin, 2014 .

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder to reveal frequency of clinically relevant genomic alterations.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Use of next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in diverse solid tumor types: The Foundation Medicine (FMI) experience with 2,200+ clinical samples.

R. Yelensky, D. Lipson, V. Miller, 2013 .

Inhibiting MEK in MAPK pathway-activated myeloma

B. Barlogie, G. Morgan, V. Miller, 2015, Leukemia.

Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes.

James X. Sun, R. Yelensky, D. Lipson, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Comprehensive genomic profiling of anal squamous cell carcinoma to reveal frequency of clinically relevant genomic alterations in the PI3K/mTOR pathway.

James X. Sun, P. Stephens, R. Yelensky, 2015 .

Safety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment

T. Ho, M. Atkins, Siraj M. Ali, 2019, Annals of Oncology.

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma

P. Stephens, S. Signoretti, T. Choueiri, 2018, British Journal of Cancer.

Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.

K. Hess, D. Carbone, R. Salgia, 2018 .

Abstract LB-178: Genomic profiling of 1239 diverse pediatric cancers identifies novel discoveries across tumors

P. Stephens, D. Lipson, V. Miller, 2016 .

A patient with complex multiple genomic ALK alterations

Siraj M. Ali, C. Abendroth, C. Jamis-Dow, 2016, Thorax.

A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib

V. Miller, R. Erlich, Siraj M. Ali, 2014, Case Reports in Oncology.

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker

Erich A. Peterson, Caleb K. Stein, O. Stephens, 2017, Blood Cancer Journal.

BRAF: An emerging target for triple-negative breast cancer.

P. Stephens, V. Miller, J. Albanell, 2017 .

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer

L. Pusztai, B. Leyland-Jones, D. Lipson, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations.

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.

J. Sosman, V. Miller, G. Daniels, 2019, The oncologist.

General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.

P. Stephens, V. Miller, G. Frampton, 2017, Human Pathology.

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.

J. Ross, E. Sokol, V. Miller, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Correlation between findings from comprehensive genomic profiling and targeted therapy response in metastatic renal cell carcinoma.

P. Stephens, T. Ho, T. Choueiri, 2016 .

B. Halmos, V. Miller, Siraj M. Ali, 2014, Cancer biology & therapy.

Renal carcinoma associated with a novel succinate dehydrogenase A mutation: a case report and review of literature of a rare subtype of renal carcinoma.

G. Netto, Siraj M. Ali, O. Sanli, 2015, Human pathology.

Molecular profile of synchronous metastatic colon cancer and anaplastic thyroid cancer in a patient with Lynch Syndrome.

Siraj M. Ali, D. Cognetti, M. Tuluc, 2015 .

Unique genomic features in adolescent and young adult, as compared to older adult, non‐Hodgkin lymphoma and potential therapeutic targets

P. Stephens, R. Yelensky, D. Lipson, 2017, British journal of haematology.

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.

G. Bhanot, E. White, R. DiPaola, 2016, The Journal of clinical investigation.

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected

A. Drilon, F. Nicolantonio, A. Bardelli, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Chang S. Chan, E. Cuppen, L. Wessels, 2022, Nature.

Frequency of genomic biomarkers of response to immunotherapy in sarcoma.

E. Sokol, V. Miller, G. Frampton, 2018 .

Identification of ANLN as ETV6 partner gene in recurrent t(7;12)(p15;p13): a possible role of deregulated ANLN expression in leukemogenesis

V. Miller, P. Campregher, Siraj M. Ali, 2015, Molecular Cancer.

Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.

R. Yelensky, D. Lipson, V. Miller, 2013, Gynecologic oncology.

Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations

S. Karam, D. Raben, Siraj M. Ali, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Comprehensive Genomic Profiling (CGP) of Angioimmunoblastic T-Cell Lymphoma (AITL) to Prospectively Inform Diagnosis and Clinical Management

R. Yelensky, D. Lipson, V. Miller, 2015 .

Clinical response to everolimus in a patient with Hodgkin's lymphoma harboring a TSC2 mutation

J. Ross, P. Campregher, Siraj M. Ali, 2016, Blood Cancer Journal.

Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer

E. Sokol, Piyush B. Gupta, G. Frampton, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

L. Wessels, G. Abou-Alfa, Siraj M. Ali, 2022, Nature.

OA 18.03 Genomic Profiling Reveals Hedgehog Pathway Alterations in Vismodegib Sensitive Lung Squamous Cell Carcinoma

V. Miller, Siraj M. Ali, A. Dowlati, 2017 .

Kinase fusions in colorectal cancers: A unique biologic subset.

S. Ou, V. Miller, M. Fakih, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton

D. Guertin, D. Sabatini, H. Erdjument-Bromage, 2004, Current Biology.

Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.

David L. Masica, R. Yelensky, R. Karchin, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

P2.03b-068 The Druggable Mutation Landscape of Lung Adenocarcinoma: Topic: Biomarkers

P. Stephens, V. Miller, G. Frampton, 2017 .

Tumor mutational burden (TMB) and co-existing actionable mutations in biliary tract cancers (BTC).

F. Meric-Bernstam, T. Bekaii-Saab, Siraj M. Ali, 2017 .

3007 Comprehensive genomic profiling characterizes the cpectrum of non-V600E activating BRAF alterations Including BRAF fusions in lung cancer

P. Stephens, R. Yelensky, D. Lipson, 2015 .

Abstract 3576: Broad analysis of recurrent somatic mutations in cancer reveals a common novel non-coding mutation in the promoter of PMS2 associated with greatly increased tumor mutation load

L. Garraway, P. Stephens, R. Yelensky, 2016 .

SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association

R. Erlich, D. Lin, Siraj M. Ali, 2019, Modern Pathology.

An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis.

L. Mariani, Siraj M. Ali, D. Raggi, 2019, European urology.

Comprehensive genomic sequencing of prostate sarcomatoid carcinoma tumors identifies differences in genomic alterations compared to prostate adenocarcinoma tumors.

P. Stephens, V. Miller, S. Millis, 2017 .